Suppr超能文献

靶向脂肪酸生物合成以开发抗结核分枝杆菌的新型化疗药物:A环修饰二苯醚作为高亲和力InhA抑制剂的评估

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.

作者信息

Boyne Melissa E, Sullivan Todd J, amEnde Christopher W, Lu Hao, Gruppo Veronica, Heaslip Darragh, Amin Anita G, Chatterjee Delphi, Lenaerts Anne, Tonge Peter J, Slayden Richard A

机构信息

Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.

出版信息

Antimicrob Agents Chemother. 2007 Oct;51(10):3562-7. doi: 10.1128/AAC.00383-07. Epub 2007 Jul 30.

Abstract

Structure-based design was used to develop a focused library of A-ring-modified diphenyl ether InhA inhibitors. From this library of analogs, two high-affinity alkyl-substituted diphenyl ethers, 6PP and 8PP, were selected for advanced study into their in vitro activity against Mycobacterium tuberculosis clinical isolates, their in vivo properties, and their signature response mode of action. 6PP and 8PP demonstrated enhanced activity against whole bacteria and showed activity in a rapid macrophage model of infection. In addition, transcriptional profiling revealed that the A-ring modifications of 6PP and 8PP increased the specificity of each analog for InhA. Both analogs had substantially longer half-lives in serum than did the parent compound, exhibited a fivefold reduction in cytotoxicity compared to the parent compound, and were well tolerated when administered orally at 300 mg/kg of body weight in animal models. Thus, the A-ring modifications increased the affinity and whole-cell specificity of the compounds for InhA and increased their bioavailability. The next step in optimization of the pharmacophore for preclinical evaluation is modification of the B ring to increase the bioavailability to that required for oral delivery.

摘要

基于结构的设计被用于开发一个A环修饰的二苯醚InhA抑制剂的聚焦文库。从这个类似物文库中,选择了两种高亲和力的烷基取代二苯醚6PP和8PP,对它们针对结核分枝杆菌临床分离株的体外活性、体内特性及其独特的作用方式进行深入研究。6PP和8PP对完整细菌表现出增强的活性,并在快速巨噬细胞感染模型中显示出活性。此外,转录谱分析表明,6PP和8PP的A环修饰提高了每个类似物对InhA的特异性。与母体化合物相比,这两种类似物在血清中的半衰期都长得多,细胞毒性降低了五倍,并且在动物模型中以300mg/kg体重口服给药时耐受性良好。因此,A环修饰提高了化合物对InhA的亲和力和全细胞特异性,并提高了它们的生物利用度。在临床前评估中优化药效团的下一步是修饰B环,以将生物利用度提高到口服给药所需的水平。

相似文献

3
Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2016 Dec;101:8-14. doi: 10.1016/j.tube.2016.07.016. Epub 2016 Aug 3.
4
Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents.
Drug Des Devel Ther. 2016 Jul 18;10:2299-310. doi: 10.2147/DDDT.S104037. eCollection 2016.
5
First triclosan-based macrocyclic inhibitors of InhA enzyme.
Bioorg Chem. 2020 Jan;95:103498. doi: 10.1016/j.bioorg.2019.103498. Epub 2019 Dec 6.
7
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. doi: 10.1016/j.bmcl.2008.04.038. Epub 2008 Apr 18.
8
Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Arch Pharm (Weinheim). 2016 Nov;349(11):817-826. doi: 10.1002/ardp.201600186. Epub 2016 Oct 24.
9
Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
Bioorg Med Chem. 2020 Nov 15;28(22):115744. doi: 10.1016/j.bmc.2020.115744. Epub 2020 Sep 8.

引用本文的文献

2
Imidazoquinoline Derivatives as Potential Inhibitors of InhA Enzyme and .
Molecules. 2024 Jun 27;29(13):3076. doi: 10.3390/molecules29133076.
4
Structure-activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting -FtsZ as antitubercular agents.
RSC Med Chem. 2020 Oct 16;12(1):78-94. doi: 10.1039/d0md00256a. eCollection 2021 Jan 1.
8
Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response.
PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005209. doi: 10.1371/journal.pntd.0005209. eCollection 2017 Jan.
9
Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2016 Dec;101:8-14. doi: 10.1016/j.tube.2016.07.016. Epub 2016 Aug 3.

本文引用的文献

3
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2006 Apr;50(4):1245-50. doi: 10.1128/AAC.50.4.1245-1250.2006.
6
Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis.
Antimicrob Agents Chemother. 2004 Jul;48(7):2415-23. doi: 10.1128/AAC.48.7.2415-2423.2004.
8
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
Mol Microbiol. 2000 Nov;38(3):514-25. doi: 10.1046/j.1365-2958.2000.02145.x.
9
The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.
Microbes Infect. 2000 May;2(6):659-69. doi: 10.1016/s1286-4579(00)00359-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验